Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Swing Therapeutics

Explore full profile

Provides digital therapeutics for people with chronic conditions

San Francisco, United StatesFounded 2019Health Tech & Medtech
Valuation $50–100M Last recorded · 2025
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Swing Therapeutics and the history behind them.

About Swing Therapeutics

Swing Therapeutics is a healthcare startup that leverages software-based treatments to improve the lives of patients suffering from chronic conditions, specifically fibromyalgia. The company operates in the digital health market, focusing on providing non-drug, evidence-backed behavioral therapies. Swing Therapeutics aims to increase access to effective treatments through its digital platform, making it easier for patients to manage their symptoms and improve their quality of life.

The primary clientele of Swing Therapeutics includes individuals diagnosed with fibromyalgia, a chronic condition characterized by widespread pain, sleep disturbances, and psychological distress. The company’s flagship product, Stanza, is a digital behavioral therapy program designed to help these patients manage their symptoms. Stanza has shown promising results in clinical trials, with significant improvements in pain severity, sleep quality, and overall well-being.

Swing Therapeutics operates on a business model that combines healthcare expertise with advanced software solutions. The company generates revenue by offering its digital therapy program to patients, either directly or through partnerships with healthcare providers and insurance companies. By providing a scalable and effective treatment option, Swing Therapeutics aims to reduce the burden on traditional healthcare systems and offer a cost-effective alternative to medication-based therapies.

The company’s approach is backed by rigorous clinical research, including multiple randomized controlled trials and real-world studies. These studies have demonstrated the safety and efficacy of Stanza, with no treatment-related safety events reported. The support of the FDA further validates the potential of Swing Therapeutics’ digital therapy as a viable treatment option for fibromyalgia.

In summary, Swing Therapeutics is revolutionizing the management of fibromyalgia through its innovative, software-based behavioral therapy. By focusing on patient well-being and leveraging clinical expertise, the company is poised to make a significant impact in the digital health market.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2019
Headquarters
San Francisco, United States
Employees
19
Open positions
None listed
Dealroom signal
68.7/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Digital Therapeutics, Tech for Biotech and Pharma, Tech for Patients, Hard Tech
Business model
SaaS
Client focus
b2b

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jul 2026 $0 — XRHealth ↗
EARLY VCOther financing Sep 2025 $11M $44M Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Swing Therapeutics website traffic

Latest recorded traffic for Swing Therapeutics is 12K monthly website visits, up 20% over the last three months. Swing Therapeutics's team declined 17.4% over the past year.

Latest monthly visits12K 3-month web change+20% 1-year team growth-17.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • JAZZ Venture Partners

Series A7 investors entered at this stage

Other known investors2 additional known investors

  • XRHealth
  • Nucleate
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Swing Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Swing Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.